Table 1.
Correlation between ALDOA expression and clinicopathological characters in patients with ccRCC
| Variables | Patients
|
ALDOA expression
|
P-value* | |
|---|---|---|---|---|
| n=162 | Low (n=82) | High (n=80) | ||
| Age, year (mean ± SD) | 52.6±10.6 | 52.1±10.5 | 53.1±10.6 | 0.811 |
| Sex | 0.153 | |||
| Female | 58, 37.7% | 25, 30.5% | 33, 41.3% | |
| Male | 104, 62.3% | 57, 69.5% | 47, 58.8% | |
| Tumor size, cm (mean ± SD) | 4.5±2.5 | 4.0±2.3 | 5.0±2.6 | 0.021 |
| TNM stage (AJCC) | 0.034 | |||
| I | 38 | 26, 31.7% | 12, 15.0% | |
| II | 62 | 32, 39.0% | 30, 37.5% | |
| III | 55 | 22, 26.8% | 33, 41.3% | |
| IV | 7 | 2, 2.4% | 5, 6.3% | |
| pT stagea | 0.148 | |||
| T1 | 42, 25.9% | 27, 32.9% | 15, 18.8% | |
| T2 | 72, 44.4% | 35, 42.7% | 37, 46.3% | |
| T3 | 41, 25.3% | 18, 22.0% | 23, 28.8% | |
| T4 | 7, 4.3% | 2, 2.4% | 5, 6.3% | |
| pN stagea | 0.020 | |||
| Nx-N0 | 133, 82.1% | 73, 89.0% | 60, 75.0% | |
| N1 | 29, 17.9% | 9, 11.0% | 20, 25.0% | |
| Fuhrman grade | 0.370 | |||
| 1 | 44, 27.2% | 25, 30.5% | 19, 23.8% | |
| 2 | 60, 37.0% | 33, 40.2% | 27, 33.8% | |
| 3 | 37, 22.8% | 15, 18.3% | 22, 27.5% | |
| 4 | 21, 13.0% | 9, 11.0% | 12, 15.0% | |
| ISUP/WHO | 0.163 | |||
| G1 | 42 | 25, 30.5% | 17, 21.2% | |
| G2 | 57 | 32, 39.0% | 25, 31.3% | |
| G3 | 44 | 18, 22.0% | 26, 32.5% | |
| G4 | 19 | 7, 8.5% | 12, 15.0% | |
| Necrosis | 0.644 | |||
| Absent | 126, 77.8% | 65, 79.3% | 61, 76.3% | |
| Present | 36, 22.2% | 17, 20.7% | 19, 23.8% | |
| MVI | 0.176 | |||
| Absent | 136, 84.0% | 72, 87.8% | 64, 80.0% | |
| Present | 26, 16.0% | 10, 12.2% | 16, 20.0% | |
Notes:
a
The pT and pN stages were classified according to 2010 AJCC TNM classification.
*
Student’s t-test for continuous variables and χ2-test for categorical variables.
Abbreviations: MVI, microvascular invasion; ISUP, International Society of Urological Pathology; SD, standard deviation; WHO, World Health Organization; ALDOA, Aldolase A; AJCC, American Joint Committee on Cancer.